Please provide your email address to receive an email when new articles are posted on . The study, which was presented at the virtual PCR e-Course and simultaneously published in Circulation, also ...

A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...

AGGREGATION of platelets in the presence of adenosine diphosphate (ADP) appears to be important in hæmostasis and in the genesis of platelet thrombosis. There is evidence that this reaction is common ...

Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container. Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.

SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. announced positive data from the company’s completed phase 1 clinical study of RUC-4 which was published in the Journal of the American Heart ...

Please provide your email address to receive an email when new articles are posted on . Patients with STEMI undergoing primary PCI achieved better platelet inhibition by chewing a loading dose of ...

The first study to examine the effects of whole-chocolate consumption on ex vivo platelet function has shown that dark chocolate acutely reduces collagen-stimulated platelet aggregation and reduces ...

SAN DIEGO---CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa inhibitor, ...

SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions in the fifth paragraph. The corrected release ...

SAN FRANCISCO (MarketWatch) -- Inspire Pharmaceuticals Inc. said late Monday that it has terminated its Phase II clinical trial of INS50589 Antiplatelet, based on the unanimous recommendation of its ...